Fidelity leads $97m Series C round in Chinese biopharma Antengene

Fidelity leads $97m Series C round in Chinese biopharma Antengene

Laboratory equipment. Photo: Pixabay

20 July, 2020

Antengene Corporation biopharmaceutical Fidelity Management & Research Company

Printed by Unregistered user on Tue, 22 Jul 2025 08:39:04 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Qiming-backed biopharma firm Gan & Lan seeks to raise $359m in Shanghai IPO

Chinese biopharma firm JW Therapeutics nets $100m in Series B round

Read more from Greater China

Venture Capital

Startup funding in Greater China grows 13% in Q2 on Ximalaya’s $2.4b deal

Cannot rely solely on valuation metrics for AI investments: Cathay Innovation